NCT05020483 - FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients | Biotech Hunter

Timeline

Start Date

October 31, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Cardiac Disease

Interventions

DRUG

FEIBA

Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.

DRUG

Placebo

Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.